Universal cell therapy targets

The term Universal cell therapy targets does not refer to a single biological molecule or receptor, but rather to a broad category of molecular targets used in the development of allogeneic or off-the-shelf cell therapies. In the context of Chimeric Antigen Receptor (CAR) T-cell therapy, this category typically encompasses two distinct groups of targets: those on the therapeutic cell itself that are modified to enable universal use, and those on the tumor cells that are targeted by universal adapter systems. To create universal cells, researchers often target and disrupt the T-cell receptor alpha constant (TRAC) to prevent graft-versus-host disease and Beta-2 microglobulin (B2M) to reduce HLA-mediated rejection by the host immune system. Alternatively, universal CAR systems utilize a modular approach where a single engineered T-cell can target multiple different antigens via soluble adapter molecules, such as biotin or fluorescein-labeled antibodies. Because this entry represents a conceptual grouping of various proteins and genes rather than a specific therapeutic target, it cannot be characterized by a single molecular classification or mechanism of action.

Other names

Universal CAR-T targetsOff-the-shelf cell therapy targetsAllogeneic cell therapy targets

Not applicable as this refers to a category of targets rather than a single molecule.